Travere Therapeutics, Inc. TVTX
Set alert
As of Nov 3, 12:35 PM ET
- YTD
- +22.98%
- 1 year
- +36.09%
- Open
- 46.52
- Prev close
- 49.26
- Mkt cap
- 4.43B
- Vol
- 4.28M
- Avg vol
- 1.79M
- EPS
- -0.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 44.73
- High
- 47.75
- Forward P/E
- 9.14
- Beta
- 1.12
- Short ratio
- 5.59
- Inst. own
- 116.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 18, 2027
- 50-d avg
- 59.06
- 200-d avg
- 46.62
- 1y target
- 75.21
5D chart
Events in this range
- Nov 2, 2026Earnings: -0.55; estimate -0.09842; surprise -458.83%
Signals (102)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 12:00 PM | 35 minutes ago |
| SMA: Bullish | Nov 3, 12:00 PM | 35 minutes ago |
| SMA: Bearish | Nov 3, 11:20 AM | 1 hour ago |
| SMA: Bullish | Nov 3, 11:05 AM | 1 hour ago |
| SMA: Bearish | Nov 3, 10:45 AM | 1 hour ago |
| MACD: Buy Signal | Nov 3, 10:25 AM | 2 hours ago |
| SMA: Bullish | Nov 3, 10:15 AM | 2 hours ago |
| SMA: Bearish | Nov 3, 9:30 AM | 3 hours ago |
| RSI: Oversold | Nov 3, 9:30 AM | 3 hours ago |
| MACD: Sell Signal | Nov 2, 4:00 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 3:35 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 2:35 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 2:30 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 2:20 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 2:15 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 22 hours ago |
Newest 20 of 102.
News
12 hours ago seekingalpha.com
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
17 hours ago zacks.com
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
17 hours ago marketbeat.com
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its…
17 hours ago zacks.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $0.28 per share a year ago.
18 hours ago benzinga.com
Travere Therapeutics Q3 2026 Earnings Call Transcript
Travere Therapeutics (NASDAQ:TVTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
20 hours ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
-
20 hours ago benzinga.com
Travere Therapeutics Q3 Adj. EPS $(0.31) Misses $(0.06) Estimate, Sales $224.563M Beat $195.292M Estimate
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.06) by 416.67 percent. This is a 152.54 percent decrease over…
20 hours ago businesswire.com
Travere Therapeutics Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our…
1 week ago businesswire.com
Travere Therapeutics to Report Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the…
-
1 week ago benzinga.com
Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA Nephropathy
FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual…
1 week ago businesswire.com
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may…
1 week ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 week ago zacks.com
Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 weeks ago benzinga.com
FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades
FTC and 7 states seek contempt against Martin Shkreli, alleging he violated his lifetime pharma ban by trading biotech stocks and influencing markets.
3 weeks ago businesswire.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement…
1 month ago businesswire.com
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American…
1 month ago prnewswire.com
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX)…
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.
1 month ago defenseworld.net
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Time to Sell?
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report)'s stock price gapped down before the market opened on Tuesday. The stock had previously closed at $62.86, but opened at $60.37. Travere…
1 month ago gurufocus.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Paten
1 month ago businesswire.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent…
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.
-
1 month ago benzinga.com
Travere Therapeutics Appoints Bradley L. Campbell President, CEO, Effective Dec. 1, Succeeding Eric Dube
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his…
1 month ago businesswire.com
Travere Therapeutics Announces Planned Chief Executive Officer Transition
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief…
1 month ago defenseworld.net
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stock
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) EVP Peter Heerma sold 8,282 shares of the company's stock in a transaction on Thursday, September 17th. The stock was sold at an average…
1 month ago defenseworld.net
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $2,337,750.00 in Stock
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) insider Elizabeth Reed sold 37,500 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold…
1 month ago businesswire.com
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday,…
1 month ago defenseworld.net
Bank of America Corp DE Invests $259.53 Million in Travere Therapeutics, Inc. $TVTX
Bank of America Corp DE acquired a new stake in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) in the second quarter, according to the company in its most recent Form 13F filing with the SEC.…
1 month ago businesswire.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants…
-
2 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $68 to $78.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75
TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $60 to $75.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $85.
-
3 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $60 to $68.
3 months ago benzinga.com
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies recording gains in today's session.
-
3 months ago benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $75
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $65 to $75.
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. Estrella Immunopharma…
3 months ago benzinga.com
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On
Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $62.
-
4 months ago benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $65.
-
4 months ago benzinga.com
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $55 to $61.
-
4 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $52 to $60.
-
4 months ago benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
-
4 months ago benzinga.com
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65
Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $50 to $65.
-
5 months ago benzinga.com
Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In Treatment Of Focal Segmental Glomerulosclerosis
Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria…
-
5 months ago benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $62
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $59 to $62.
-
5 months ago benzinga.com
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $55 price target.